Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s stock price dropped 1.6% on Tuesday . The company traded as low as C$6.66 and last traded at C$6.66. Approximately 270,220 shares were traded during mid-day trading, an increase of 3,547% from the average daily volume of 7,410 shares. The stock had previously closed at C$6.77.
Eupraxia Pharmaceuticals Stock Performance
The business’s 50-day moving average is C$6.44 and its 200-day moving average is C$7.22.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
